已收盘 04-02 16:00:00 美东时间
+0.300
+4.73%
今日重点评级关注:Evercore ISI集团:维持Caribou Biosciences"跑赢大市"评级,目标价从11美元升至13美元;富国银行:上调uniQure评级至"超配",目标价从15美元升至60美元
03-10 15:05
Stifel analyst Tom Stephan maintains RxSight (NASDAQ:RXST) with a Hold and lowers the price target from $10 to $9.
03-09 20:46
今日重点评级关注:HC Wainwright & Co.:维持NovoCure"买入"评级,目标价从47美元升至49美元;Citizens:维持Ironwood医药"跑赢大市"评级,目标价从8美元升至10美元
02-27 11:07
RxSight (NASDAQ:RXST) has been analyzed by 5 analysts in the last three months,...
02-27 05:01
Needham analyst David Saxon reiterates RxSight (NASDAQ:RXST) with a Buy and maintains $13 price target.
02-26 20:23
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据RxSight业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **2025年第四季度业绩:** - 总营收:3,260万美元,同比下降19% - 毛利率:77.5%,同比上升(2024年Q4为71.6%) - 净亏损:920万美元(每股亏损0.22美元),2024年Q4数据未提及具体对比 - 调整后净亏损:130万美元(每股亏损0.03美元),剔除780万美元股权激励费用 - 销售及管理费用:2,770万美元,同比下降2% - 研发费用:890万美元,同比下降3%,环比下降2% **2025年全年业绩:** - 总营收:1.345亿美
02-26 12:37
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.33) by 90.96 percent. This is a 200 percent decrease over earnings of $0.03 per share from the same
02-26 05:14
Companies Reporting Before The Bell • Clear Secure (NYSE:YOU) is expected to re...
02-25 19:11
今日重点评级关注:HC Wainwright & Co.:维持Soleno Therapeutics"买入"评级,目标价从110美元升至120美元;富国银行:维持Soleno Therapeutics"超配"评级,目标价从106美元升至114美元
01-21 11:42
Across the recent three months, 5 analysts have shared their insights on RxSigh...
01-21 04:00